Fierce Pharma Asia—Takeda restructures; Lilly, Innovent tout GLP-1 win; BIO warns of decoupling damage
Takeda has entered into a restructuring to achieve “organizational simplicity.” Innovent Biologics' GLP-1R/GCGR dual agonist, licensed from Eli Lilly, has notched a second positive phase 3 readout. A BIO survey of biopharma companies indicated that …